UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2005
US Oncology, Inc.
(Exact name of registrants as specified in their charters)
(State or other jurisdiction of incorporation or organization) Delaware |
| (Commission File Numbers) 0-26190 |
| (I.R.S. Employer Identification No.) 84-1213501 |
16825 Northchase Drive, Suite 1300
Houston, Texas 77060
(Address of Principal Executive Offices)
(832) 601-8766
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under Exchange Act (17 CFR 240-14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On March 16, 2005, US Oncology, Inc. issued a press release announcing that its parent company, US Oncology Holdings, Inc., has entered into an agreement to sell an aggregate $250 million principal amount of senior unsecured floating rate notes due 2015. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Exhibit No. |
| Description |
|
|
|
|
|
99.1 |
| US Oncology, Inc.’s press release dated March 16, 2005. |
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 16, 2005 | By: | /s/ PHILLIP H. WATTS |
|
|
| Phillip H. Watts |
|
|
| General Counsel |
|
3